It’s My Time

After Global Blood Therapeutics received FDA approval for its novel sickle cell treatment Oxbryta (voxelotor) in November 2019, RIESTER RX conducted a series of qualitative and quantitative concept testing research to evaluate potential Sickle Cell Disease campaigns.

The most impactful campaign featured real Sickle Cell Disease patients who experienced life-changing results due to their treatment with Oxbryta. RIESTER RX created this upbeat and energetic campaign to spread the good news about the newest sickle cell treatment option available.